You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer
|
|---|---|
| Published in |
Clinical Cancer Research, May 2011
|
| DOI | 10.1158/1078-0432.ccr-10-1969 |
| Pubmed ID | |
| Authors |
Heather L. McArthur, Hope Rugo, Benjamin Nulsen, Laura Hawks, Jill Grothusen, Michelle Melisko, Mark Moasser, Matthew Paulson, Tiffany Traina, Sujata Patil, Qin Zhou, Richard Steingart, Chau Dang, Monica Morrow, Peter Cordeiro, Monica Fornier, John Park, Andrew Seidman, Diana Lake, Theresa Gilewski, Maria Theodoulou, Shanu Modi, Gabriella D'Andrea, Nancy Sklarin, Mark Robson, Mary Ellen Moynahan, Steven Sugarman, Jane E. Sealey, John H. Laragh, Carmen Merali, Larry Norton, Clifford A. Hudis, Maura N. Dickler |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 3% |
| Unknown | 60 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 21% |
| Student > Ph. D. Student | 8 | 13% |
| Student > Master | 8 | 13% |
| Other | 6 | 10% |
| Student > Bachelor | 4 | 6% |
| Other | 14 | 23% |
| Unknown | 9 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 44% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 11% |
| Agricultural and Biological Sciences | 7 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Chemistry | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 10 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2017.
All research outputs
#4,761,657
of 23,039,416 outputs
Outputs from Clinical Cancer Research
#4,333
of 12,651 outputs
Outputs of similar age
#24,252
of 111,018 outputs
Outputs of similar age from Clinical Cancer Research
#50
of 144 outputs
Altmetric has tracked 23,039,416 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,651 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 111,018 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 144 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.